Table I.
Androgen receptor expression and its association with clinicopathological features and prognosis in bladder cancer.
| Tumor vs. non-tumor, n (%) | Tumor grade, n (%) | Tumor stage, n (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Authors, year | Nation | n | Method | Tumor | Non-tumor | Low | High | NI | MI | Prognosis | (Refs.) |
| Zhuang et al, 1997 | Finland | 9 | IHC scorea | 4/9 (44.4) | NA | NA | NA | 1/5 (20.0) | 3/4 (75.0) | NA | (8) |
| Boorjian et al, 2004 | USA | 49 | IHC scoreb | 26/49 (53.1) | 32/37 (86.5) | 8/9 (88.9) | 16/33 (48.5) | 21/28 (75.0) | 3/14 (21.4) | NA | (9) |
| Boorjian et al, 2009 | USA | 55 | IHC (5%)c | 24/55 (43.6) | NA | NA | NA | 13/22 (59.1) | 11/33 (33.3) | NA | (10) |
| Mir et al, 2011 | USA | 472 | IHC scoreb,d | 61/472 (12.9) | NA | 11/90 (12.2) | 50/382 (13.1) | 15/167 (9.0) | 46/305 (15.1) | RFS | (11) |
| Tuygun et al, 2011 | Turkey | 139 | IHC (10%)c | 71/139 (51.1) | 0/58 (0) | 46/72 (63.9) | 25/67 (37.3) | 64/106 (60.4) | 7/33 (21.2) | RFS/PFS | (19) |
| Zheng et al, 2011 | USA | 24 | IHC scored | 8/24 (33.3) | NA | NA | NA | 2/5 (40.0) | 6/19 (31.6) | PFS | (20) |
| Miyamoto et al, 2012 | USA | 188 | IHC scored | 79/188 (42.0) | 113/141 (80.1) | 31/56 (55.4) | 48/132 (36.4) | 49/97 (50.5) | 30/91 (33.0) | RFS/PFS | (21) |
| Mashhadi et al, 2014 | Iran | 120 | IHC (10%)c | 26/120 (21.7) | 0/132 (0) | NA | NA | NA | NA | NA | (22) |
| Nam et al, 2014 | Korea | 169 | IHC (10%)c | 63/169 (37.3) | NA | 47/120 (39.2) | 16/49 (32.7) | NA | NA | RFS/PFS | (23) |
| Jing et al, 2014 | China | 58 | IHC scored | 31/58 (53.4) | NA | 22/40 (55.0) | 9/18 (50.0) | 22/45 (48.9) | 9/13 (69.2) | NA | (24) |
| Williams et al, 2015 | USA | 297 | IHC scorea | 73/297 (24.6) | NA | NA | NA | 36/107 (33.6) | 37/190 (19.5) | NA | (25) |
| Izumi et al, 2016 | Japan | 72 | IHC (10%)c | 44/72 (61.1) | 35/42 (83.3) | NA | NA | NA | NA | RFS | (26) |
a
Score method not specified
b
score according to the percentage of nuclei staining
c
percentage represents the staining cutoff value that was considered as positive
d
score according to the percentage of positive cells and staining intensity. NI, non-invasive; MI, muscle invasive; RFS, recurrence-free survival; PFS, progression-free survival; IHC, immunohistochemistry; NA, not applicable.